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varied, this study aimed to review the characteristics of ongoing studies of incentive-
based interventions. Methods: A targeted search was conducted in ClinicalTrials.
gov using the search terms “incentive”, “reward”, “contingency”, “contingency man-
agement”, “prize”, “reinforcement”, “token”, “voucher”, “conditional cash transfer”, 
“CCT, “pay for performance” or “P4P”. Studies were selected for inclusion if they 
investigated the use of ≥ 1 incentive in modifying health-related behaviour, had 
the status “active, not recruiting,” and the effect of incentives was distinguishable 
between study arms. Results: Of the 204 search results, 42 met the inclusion cri-
teria. The majority of these studies (n= 29) took place in North America, and almost 
half (n= 20) investigated the use of a financial reward or voucher as the incentive. The 
rationale for the use of an incentive was most commonly the promotion of healthy 
lifestyle choices relating to diet and physical activity (n= 17), whilst other studies 
targeted behaviours such as medication/treatment adherence (n= 9) or breaking 
addiction (n= 8). The use of incentives in the management of chronic conditions 
or diseases such as hypertension, diabetes or HIV was investigated in 11 of the 
included studies. ConClusions: These initial results show that ongoing studies 
of incentives predominantly investigate the promotion of healthy lifestyle choices, 
with financial rewards or vouchers being the most common form of incentive. This 
emphasis on promoting healthy lifestyle choices may reflect the difficulties that 
individuals otherwise have in achieving these complex behavioural changes, and 
perhaps the importance of these changes to healthcare systems worldwide. Studies 
which assess the use of inventive-based interventions for modifying health-related 
behaviours, or compare the effectiveness of different incentives in improving out-
comes, warrant further investigation.
PRM238
A Mixed Methods study of ReseARcheRs’ exPeRiences of develoPing 
coRe outcoMe sets
Gargon E, Young B, Williamson PR
University of Liverpool, Liverpool, England
objeCtives: A core outcome set (COS) is a standardised set of outcomes which should 
be measured and reported, as a minimum, in all effectiveness trials for a specific 
health area. A systematic review of COS identified 198 COS [1]. A range of methods 
were used, and furthermore, 164/178 studies that described the methods used did not 
provide an explanation regarding their choice of methodology. There is little guidance 
about how to conduct or report COS studies and it is currently uncertain which of 
these methods are the most suitable, feasible and efficient. It is important to inves-
tigate COS developers’ choice of approach as this is a new area of research, and in 
order to formulate guidance in this area we need to try and understand the current 
situation, including the influences of methodological choices being made. Methods: 
We have used a mixed methods approach, using qualitative methods (semi-structured 
interviews) and a web-based survey. Results: Interviews are currently underway. 
The survey was sent out to 169 COS developers, with 81/169 responses. Methodological 
decisions were based most commonly on previous work, expert advice or own expe-
rience. Challenges of this work included resources (time, funding and technology), 
achieving consensus, a lack of data and challenges with involving patients in the 
process. ConClusions: In order to develop methodological guidance for COS devel-
opment we need to try to understand what factors have informed the ways in which 
researchers have developed COS. This is the first insight into COS developers’ choice 
of methodology and their experiences of the process. These results will provide a more 
comprehensive account of COS development, ultimately facilitating the formulation 
of guidance in this area. Gargon E, Gurung B, Medley N, Altman DG, Blazeby JM, Clarke 
M, Williamson PR: choosing important health outcomes for comparative effectiveness 
research: a systematic review. PLoS ONE 2014,9:e99111.
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objeCtives: The growing market for personal wellness technology has increased 
the awareness of the potential role of sleep and activity measures in clinical trials. 
However there is significant debate around the clinical value of these endpoints, 
position of the devices and duration of the recording period. 90 Industry Sponsored 
Trials were identified from a comprehensive review of Clinical Trials.gov, EU Clinical 
Trials Register and The International Standard Randomised Controlled Trial Number 
register (ISRCTN) as having used Actigraphy (activity and sleep) derived outcome 
measures. This retrospective analysis is designed to establish if there is commonality 
among the existing Actigraphy endpoints and study design that can provide a frame-
work for future clinical trials. Methods: Systematic review of the subset of industry 
sponsored trials which had been filtered using the word “Actigraphy” and the brand 
names of the best known devices. These trials were then subdivided by therapeutic 
areas and analysed for outcome measures and study design. Results: Therapeutic 
Areas (CNS, Dermatology, Respiratory, Cardiovascular, Diabetes, Oncology), Discrete 
and Common Endpoints: Sleep (47%), Activity (23%), PLM (12%). Wear time: when 
stated varied from 10 hours to 4 weeks. ConClusions: The preponderance of the 
trials reviewed were in the CNS therapeutic area (73%). Actigraphy derived endpoints 
were used both as primary and secondary outcome measures. Sleep endpoints were 
the most common outcome measures, however there was considerable variability 
regarding the sleep parameter selected, the terminology used in the protocols and the 
wear time. In order for the value of Actigraphy derived endpoints to be maximised and 
universally adopted, the choice of endpoint and study design need to be standardized.
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ment and treatment titration for maximal clinical benefit. In this paper, we pre-
sent the rationale for and implementation challenges of the Diabetes Telephone 
Study (DTS), a randomized trial designed to improve quality of life among newly 
treated DPN patients. Methods: This pragmatic cluster randomized controlled 
trial tests whether collecting and feeding back real-time patient-reported data 
about experiences with newly prescribed DPN medicines can improve treatment 
outcomes. Randomization occurred at the physician level and patients are pro-
spectively identified as they receive a new DPN-related prescription (October 2014 
- November 2015). Patients in the intervention group report on medication taking 
behavior, symptoms, side effects, self-titration and satisfaction with treatment 
during three interactive automated calls during the six months following a new 
prescription. This information is entered into the electronic medical record and, 
among patients experiencing problems (e.g., side effects), flagged for immediate 
physician follow-up. We compare outcomes (quality of life, medication changes, 
patient-physician communication) for the intervention group to those in a control 
group who receive similarly timed non-interactive automated calls consisting of 
diabetes educational messages. Results: We designed this study to minimize com-
mon threats to internal validity, including ascertainment bias and contamination. 
However, stakeholder engagement has been critical for tailoring the intervention to 
address pragmatic concerns such as provider time constraints and patient charac-
teristics. ConClusions: Innovative strategies are needed to guide improvements 
in health care delivery for patients with symptomatic DPN. If successful, this inter-
vention provides a critical information feedback loop that would optimize DPN 
medication titration through widely available interactive voice response technology.
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objeCtives: The number of patients posting on health-related social media (SM) sites 
about their experiences is increasing exponentially. There have been well-publicised 
cases where trial participants blog and discuss all kinds of details about the clinical 
trials (CTs) in which they are participating. There has been expression of concern 
that this could compromise the integrity of CTs. The primary objective of this study 
was to explore how frequently CTs were discussed in selected patient SM sites and 
to characterise the types of discussions taking place and how they might impact on 
clinical trials. Methods: Diabetes and breast cancer were selected as the target 
conditions as these have a large number of clinical trials and patient-related SM 
discussions with high participation levels. Over one million postings identified from 
the largest United States and United Kingdom-based SM sites were evaluated for 
content relating to discussion of CTs Results: Over 1 million posts were reviewed 
with 0.9% of posts mentioning clinical trials. The average number of views of post-
ings mentioning CTs were 1,025 which was just lower than the average of 1,147 for all 
posts. Discussions of active CTs by participants were rare. There were no discussions 
in the sample that risked un-blinding of CTs. There were equally discussion encour-
aging and discouraging clinical trials. Overall there were 37 threads which debated 
whether to join clinincal trials or not. Two patient SM sites had recently added CT 
specific forums. ConClusions: Use of SM by clinical trial participants is growing, 
and there is a potential for both harm and benefit in these discussions and in their 
visibility through a browser. Trial participants should undergo some basic training on 
the risks of SM discussion and those running CTs may need to consider the potential 
impact of social media on the trial and consider periodic monitoring of SM content.
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objeCtives: The questionnaire of the Cochrane Collaboration developed to assess 
risks of six key systematic biases in randomized controlled trials (RCT) is needed 
for wide use in Russia, so it was translated into Russian and validated. Methods: 
Two experts (F.V.K. and K.G.R.) with 4-year experience of evidence assessment used 
the Russian version of the questionnaire to consider biases in 20 RCT published in 
2002-2012. The inter-rater agreement was estimated using Kappa (K) coefficient, it 
was calculated for six key domains and also for overall summarizing risk of bias (low, 
high, unclear) within a study (across domains). Results: Two experts demonstrated 
good, very good and excellent agreement on each key domain and also good overall 
summarizing agreement (K= 0.767, 95% CI 0.527; 1.000). We propose to consider the 
conflict of interests not as additional but as obligatory (the 7th) key domain (the 
agreement in this domain is very good, K= 0.840, 95% CI 0.641; 1.000). As it appeared 
to influence greatly the overall estimation summarizing risk we also propose to 
modify slightly the Cochrane rule of summary assessment of the risk of bias (across 
domains). The modified rule allows unclear risk of bias in one key domain to have 
low overall summarizing risk. The final version of the document also provides good 
agreement (K= 0.785, 95% CI 0.503; 1.000). ConClusions: The Russian version of 
the Cochrane questionnaire is ready to use also as a web-based tool.
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objeCtives: Incentive-based interventions aim to improve health outcomes by 
rewarding individuals for specific health-related behaviours such as exercise, medi-
cation adherence or smoking cessation. Since the types and targets of incentives are 
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bACkgRound: The aim of this presentation is to explain why the standard cost-
effectiveness (CE) plane gives an incomplete representation of the cost-effective-
ness of intervention strategies and to show how this problem is easily solved. The 
CE plane is the standard graphical framework for presenting costs, effects and 
incremental cost-effectiveness ratios (ICERs) of alternative intervention strategies. 
Comparing multiple strategies typically yields an increasingly steep efficient fron-
tier, indicating that strategies become progressively less cost-effective as the ICER 
rises. However, standard CE planes generally do not include the cost-effectiveness 
threshold, therefore the figure itself does not identify which strategies are cost-
effective. Consequently, the CE plane does not make it clear what strategy is optimal 
and the relative scale of costs and effects in the figure is uninformative. AnAlYsis: 
A new graphical convention is proposed whereby a line with slope equal to the cost-
effectiveness threshold is added to the CE plane. While previous examples of CE 
planes have included such threshold lines, these have drawn the threshold from the 
origin, often at 45 degrees. Using published cost-effectiveness estimates from the 
literature, we show why this approach can be problematic: it does not readily iden-
tify the optimal strategy; can confuse average and incremental cost-effectiveness 
ratios; and, can impose a scale on the diagram that obscures relevant detail. Using 
the same published examples we then demonstrate the proposed alternative of 
including a threshold line which is set tangential to the frontier rather than passing 
through the origin and is not necessarily drawn at 45 degrees. This unambiguously 
identifies the optimal strategy and provides a useful scale that graphically illustrates 
which interventions are cost-effective. ConClusion: The simple inclusion of the 
threshold avoids several problems with the CE plane. It enhances the usefulness of 
the figure and better communicates which strategies are relevant and which are not.
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bACkgRound: Chronic Obstructive Pulmonary Disease (COPD) is the third main 
cause of death worldwide (WHO, 2014). For 2013, in Portugal 2,720 deaths were 
associated to COPD. Smoking is the main risk-factor and smoking cessation is 
the most effective strategy to slowdown the progression of COPD. objeCtive: To 
model the health benefits associated to early diagnosis and treatment of COPD in 
Portugal over a 20 year time-horizon. Methods: Using a stochastic individually 
based dynamic microsimulation model, health benefits were estimated as the dif-
ference in health outcomes between an intervention scenario and the status quo. 
The intervention considered is a screening program of smokers and ex-smokers 
aged 40 and over in primary healthcare settings, with selective referral to smoking 
cessation programs. In each scenario the model identifies: a) population with-
out COPD (NO-COPD); b) population with a COPD diagnosis (COPD-DIAG) and c) 
population with undiagnosed COPD (COPD-NODIAG). The calibration of the model 
assumes the mean forced expiratory volume in one second (FEV1) in individuals 
with COPD follows a normal distribution, as suggested by the literature. Following 
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, four 
severity stages were identified depending on the FEV1 value. Exacerbation fre-
quency and quality of life differ according to the stage of the individual. In each 
year, NO-COPD individuals have probabilities of transitioning to COPD according 
to sex, age and smoking habits; the FEV1 declines according to previous FEV1 level, 
smoking cessation and exacerbation episodes. Compared to COPD-NODIAG, the 
progression of the COPD-DIAG population is slower and quality of life higher due 
to medication and fewer exacerbation episodes per year. ConClusions: Early 
diagnosis and treatment of COPD may lead to substantial health gains. Modelling 
the disease evolution in order to assess the impact of future interventions is 
crucial to guide policy.
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bACkgRound: Health economic models are used to estimate the expected costs 
and health outcomes of competing decision options. Model parameters are gener-
ally uncertain, and it is often useful to quantify the value of undertaking further 
data collection in order to reduce uncertainty. An upper bound on the value of 
resolving all uncertainty regarding an input parameter is quantified by its partial 
Expected Value of Perfect Information (EVPI). The value of a specific future study 
is quantified by its Expected Value of Sample Information (EVSI). PROBLEM: The 
standard approach to computing both partial EVPI and EVSI is via a nested two-
level Monte Carlo scheme that includes at each inner loop step both parameter 
sampling and model evaluation. This scheme can be prohibitively slow for complex 
models (eg. patient-level simulation models). Additional difficulties may occur in 
the calculation of EVSI if we have to resort to Markov-chain Monte Carlo (eg. using 
WinBUGS) to generate samples from the posterior distribution of the parameters 
given the simulated data for our proposed study. These difficulties have resulted in 
the restriction of Value of Information analyses to a small subset of health economic 
evaluations. SOLUTION: We have developed fast non-parametric regression based 
methods for computing both partial EVPI and EVSI. For partial EVPI we require only 
objeCtives: Remote monitoring (RM) is useful in chronic diseases, but evidence 
is scarce in home dialysis. Sharesource™, a two way connectivity platform with 
RM capabilities, should enable earlier intervention and healthcare savings. This 
abstract describes a simulation study designed to estimate the type and impor-
tance of the savings. Methods: This study used an approach similar (although 
in a virtual environment) to that for diagnostic tests, i.e., additional information 
impact on treatment pathways. Automated peritoneal dialysis (APD) patient pro-
files (e.g., therapy non-compliance, fluid overload, etc.) were developed by a group 
of in-house nephrologists and nurses experienced in managing APD patients. Each 
patient profile was developed in 2 scenarios: “with RM” information (treatment 
data, blood pressure, weight) and “without RM”. Nephrologist (US= 4, Germany= 3, 
Italy= 2) experts in managing APD patients validated the “without RM” resources. 
The “with RM” resources were evaluated by 15 (US= 7, Germany= 4, Italy= 4) APD 
teams (1 nephrologist & 1 nurse). Resources were compared with t-tests. Results: 
Patient profile development required several rounds of individual and group 
reviews over a 6 month-period to ensure clarity of clinical event sequence and 
clinician management response. During the process, 8 profiles were abandoned, 
leaving 12 profiles for the simulation. Recruitment of experts and APD teams was 
moderately easy, the biggest hurdle was contract signature in some countries 
(e.g., Italy). Participants submitted responses, usually within two weeks. Overall, 
results indicate that RM could avoid 49-75 healthcare resources (4.1-6.2 per patient 
profile), including clinic calls/visits (48-72), but also hospitalizations (2), emer-
gency room visits (3.5-5) and transfer from APD to in-center hemodialysis (1-2.25). 
These patient profiles were perceived as representative of 17-37% of the APD 
patient population. ConClusions: This simulation was a rapid and affordable 
way of estimating the type and importance of potential reductions in healthcare 
resource consumption to be expected from RM in APD patients while waiting for 
real-world evidence.
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objeCtives: To investigate types of study design associated with classifications 
of either good or poor quality as defined by QUADAS-2, a new tool developed by 
Bristol University and used in decision-making evaluations for diagnostic technol-
ogy. Methods: A pragmatic review of studies in Medline, Embase and the Cochrane 
Library was conducted to identify the widest possible variety of study designs used 
in the autoimmune disease therapeutic area. Using QUADAS-2, each study was 
assessed for a high, low or unclear risk of bias across four domains: patient selec-
tion, index test, reference standard and patient flow. Results: A number of study 
design features in the autoimmune disease area heavily influenced the risk of bias. 
Avoidance of a case-control design had the greatest impact overall. For example, 
case-control designs that enroll participants with known disease and include a 
control group without the condition may exaggerate diagnostic accuracy (patient 
selection domain), and they would make it more likely that biomarker assessment 
would be conducted with knowledge of the clinical diagnosis (index test domain). In 
contrast, a non-case-control design would mean that clinical assessment of the dis-
ease would be performed without knowledge of the results of the biomarker assess-
ment, leading to a low risk of bias (reference standard domain). ConClusions: 
Avoidance of a case-control study design had the biggest impact on QUADAS-2 
assessment of risk of bias in autoimmune disease diagnostic studies. Studies which 
exclude difficult-to-diagnose patients, such as those presenting with symptoms in a 
genuine diagnostic setting, may over-estimate test sensitivity. It is critical to adhere 
to design features leading to a low risk of bias because decision makers will review 
the quality of diagnostic accuracy studies based on QUADAS-2.
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objeCtives: Health technology assessment (HTA) agencies apply different impor-
tance to different aspects of HTA submissions. It is therefore difficult to draw gen-
eralizable conclusions about the factors influencing subsequent recommendations. 
Previous studies have tried to identify country-specific factors, but there were differ-
ent techniques and parameters applied. The aim of this literature review is therefore 
to collate all parameters used in previous research in order to inform research into 
the predictive factors for HTA recommendations. Methods: A systematic literature 
review was performed using PubMed. Examples of search terms used are “success”, 
“HTA” and “recommendation”. The time span was from 2004 to 2015. The studies 
differed in terms of methods used, parameters used and research questions. After 
the quality of the articles was assessed, the evidence provided in the literature was 
summarized and the findings were interpreted. The parameters analysed in the stud-
ies were compared taking into account country-specific requirements. Results: Out 
of sixteen articles identified, most studies evaluated NICE (six studies), followed by 
PBAC (four studies). The remaining studies evaluated different countries. A total of 
111 parameters were identified, which were grouped in three categories: clinical, 
economic and societal factors. The predictive clinical factors showed some regular-
ity explaining the HTA recommendation. Drug superiority, RCTs and the number of 
comparators were reoccurring explanatory variables. Economic factors showed most 
consistency among the studies. For NICE, cost-effectiveness proved to be an explana-
tory factor in all studies. Societal parameters were identified less often as explanatory 
factors, but included the burden of illness and company size. ConClusions: Many 
parameters have been used in previous research to explain the HTA decision, but 
there is no agreement yet on the driving parameters explaining the HTA-decision per 
agency. Hardly any study investigated an agency different than NICE or PBAC, which 
indicates that there is a knowledge gap for other agencies.
